(138) performed whole-exome sequencing on tumor tissues from 35 untreated mRCC patients and found that loss-of-function mutations in PBRM1 were associated with enhanced responsiveness to ICIs, a finding subsequently validated in independent cohorts. This evidence concerns the gene PBRM1 and neoplasm.